Drug intelligence / Profile preview

opium + ethyl iodide

Development stage
Unknown
Modality
Nucleic Acid-Directed Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
01

Overview

This is a combination of two substances: **opium**, a natural mixture of alkaloids derived from the poppy plant (Papaver somniferum), and **ethyl iodide** (also known as iodoethane), an organoiodine compound. \n- **Opium** acts primarily as an agonist at opioid receptors in the central nervous system, producing analgesia, sedation, euphoria, respiratory depression, constipation, and other effects. Its main active components include morphine, codeine, thebaine, papaverine, and noscapine. The pharmacological effects are mediated through activation of μ-opioid (mu), δ-opioid (delta), and κ-opioid (kappa) receptors[1][5]. \n- **Ethyl iodide** is a small molecule used mainly as an ethylating agent in organic synthesis; it has no established therapeutic use or recognized mechanism of action in medicine[6]. It is not known to have any direct pharmacological effect relevant to human therapy.\n\nThere is no evidence that this specific combination has been developed or marketed for medical use. No unique brand name or clinical indication for "opium + ethyl iodide" exists in standard drug references.

Other names
opium and ethyl iodideopium plus ethyl iodide
02

Targets

DOR (Opioid Receptor Delta 1)MOR (Mu opioid receptor)KOR (Kappa opioid receptor)

Beyond the preview

Go deeper on opium + ethyl iodide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on opium + ethyl iodide.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call